TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03332680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EmbryoGlue® (laboratory culture medium)
Description: Embryos placed in this medium prior to transfer

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard control medium
Description: Embryos placed in this medium prior to transfer
Study: NCT01658644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provision of Clinical Care Handout
Description: Patients assigned to groups B or C will be provided with a paper or electronic version displaying either a list of the names and roles of their clinical care staff (group B), or a list of names and roles accompanied by the respective photograph of each clinician (group C). This document will be presented to the patient at the earliest possible time after admission to the hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provision of Clinical Care Handout
Description: Patients assigned to groups B or C will be provided with a paper or electronic version displaying either a list of the names and roles of their clinical care staff (group B), or a list of names and roles accompanied by the respective photograph of each clinician (group C). This document will be presented to the patient at the earliest possible time after admission to the hospital.
Study: NCT01170247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intranasal Ketamine (100 mg/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Intramuscular Ketamine
Study: NCT00921167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab/Irinotecan
Description: Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs \[EIAEDs\] or 340mg/m2 for patients on EIAEDs) every 2 weeks
Study: NCT02956200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
Study: NCT00826462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone
Description: Injection with triamcinolone 10 mg at start and at 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection with sodium chloride at start and at 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 10 mg of lidocaine at start and at 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: 10 mg of lidocaine at start and at 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: 12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy
Description: 12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500 mg bid for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500 mg bid for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500 mg bid for 14 days
Study: NCT00333762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Power Assistance Module (SPAM)
Description: Experimental Power wheelchair utilized to traverse prescribed course

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Wheelchair Component System (SWCS)
Description: Experimental power wheelchair utilized to traverse prescribed course
Study: NCT04140578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: inject from iv drip before endoscopic cyanoacrylateinjection obliteration
Study: NCT04755686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast-tracking
Study: NCT03012048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver-impregnated ceramic tablet
Description: A silver-impregnated ceramic disk used for drinking water treatment that was developed by engineers at the University of Virginia. When the ceramic disk is placed in a household water storage container, silver diffuses through the porous ceramic into the water at a release rate that is effective for continual disinfection of waterborne pathogens while remaining below the silver drinking water standard. The disk is effective for daily treatment of 10 to 15 liters for at least six months.~This intervention was removed from the study in July 2017 (approximately at 1 year of follow-up).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silver-impregnated ceramic water filter
Description: Silver-impregnated ceramic water filter are well-developed, tested, and widely-used devices. In addition to mechanically removing pathogens, the filter is treated with silver to reduce live pathogens that pass through the filter and to provide residual disinfectant to reduce risk of recontamination after treatment.~This intervention was replaced with ceramic filters without silver in Dec 2017 (approximately at 1.5 years of follow-up).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Safe-storage water container
Description: The safe-storage water containers used in this study are plastic buckets with a spigot, purchased locally.
Study: NCT04455152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-control
Description: avoiding eating sweets as a way of building self-control strength
Study: NCT03052400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg daily
Description: Glucocorticoid receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02314637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Description: Teneligliptin for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin + Sulfonylurea
Description: Teneligliptin for 52 weeks in combination with sulfonylurea
Study: NCT01132781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline (Intervention Group)
Description: 200 mg twice daily of slow release theophylline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Placebo Group)
Description: 200 mg twice daily of placebo drug
Study: NCT03926611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 Arm 1
Description: 10 mg LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
Study: NCT01487759

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligofructose enriched inulin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT04173897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIBERATE website
Description: The LIBERATE intervention is a self-management, symptom monitoring and signposting website tailored to the supportive needs of women living with secondary breast cancer. Components include; holistic health information specific to secondary breast cancer, symptom monitoring and self-management advice, case studies, signposting to services \& support and support for family \& loved ones.
Study: NCT01459614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV on Days 4 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: IV on Days 4 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: orally, twice a day Days 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Days 4 and 11
Study: NCT02667080

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2-7 days of Sexual abstinence
Description: 2-7 days of Sexual abstinence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 hours of sexual abstinence
Description: 2 hours of sexual abstinence
Study: NCT03926611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 Arm 2
Description: 35 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 Arm 3
Description: 100 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 Arm 4
Description: 10mg bid of LOU064 orally, twice daily from Day 1 to 85

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 Arm 5
Description: 25 mg bid of LOU064 orally, twice daily from Day 1 to 85

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 Arm 6
Description: 100 mg bid of LOU064 orally, twice daily from Day 1 to 85

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo arm
Description: Matching placebo, orally, twice daily from Day 1 to 85
Study: NCT01237899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally.
Study: NCT00500682

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9g /day (3 times a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: 9g /day (3 times a day)
Study: NCT00974987

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: BNCT(boron neutron capture therapy)
Description: BSH(sodium borocaptate) 100mg/kg iv for one hour starting 13 hours before irradiation, and BPA(p-boronophenylalanine) 500/mg/kg iv at a speed of 200mg/kg/hr for 2 hours starting 2 hours before irradiation. During irradiation, BPA iv continues at a speed of 100mg/kg/hr.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: XRT(X-ray radiation treatment)
Description: After BNCT, 2Gy irradiation every day for 12 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ(temozolomide)
Description: 75mg/m2 for day1-12. After XRT, repeat the cycle of 150-200mg/m2 for 5 days and cessation for 23 days.
Study: NCT01237899

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Administered orally.
Study: NCT02936648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality improvement intervention
Description: The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
Study: NCT01146327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110
Description: Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple oral doses of placebo will be given once daily for 2 weeks.
Study: NCT04028544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishenyiqi dropping pills
Description: on the basis of standard treatment, adding QSYQ dropping pills 1 bag each time, 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: on the basis of standard treatment, adding placebo 1 bag each time, 3 times a day
Study: NCT00207064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: flexible doses according to the clinical condition
Study: NCT03325101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryosurgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pheresis
Description: Undergo apheresis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Autologous Dendritic Cells
Description: Given IT
Study: NCT01067092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Intervention
Description: A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Newsletter
Description: Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
Study: NCT03482960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xenon gas
Description: Hyperpolarized Xenon gas~* Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)~* Administration: By mouthpiece attached to a single use Tedlar bag.~* Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.~* Frequency: 10-minute interval between doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xenon gas
Description: Hyperpolarized Xenon gas~* Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)~* Administration: By mouthpiece attached to a single use Tedlar bag.~* Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.~* Frequency: 10-minute interval between doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PFP
Description: * Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PFP
Description: * Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.
Study: NCT04599764

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS
Description: Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak direct currents.The respective excitability alterations-enhancement by anodal and reduction by cathodal tDCS-can last for over an hour after the end of stimulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: computer-based cognitive training
Description: Computer-based cognitive training (CCT) is a potentially important tool for individuals at risk of dementia. Cognitive training in healthy older adults and those at risk of dementia has been linked to benefits in cognitive functioning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: computer-based cognitive training
Description: Computer-based cognitive training (CCT) is a potentially important tool for individuals at risk of dementia. Cognitive training in healthy older adults and those at risk of dementia has been linked to benefits in cognitive functioning.
Study: NCT02637830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of fluoride varnish (22600 ppm F, Duraphat) at the begining of the study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of fluoride toothpaste (1500 ppm F, Crest) twice a day for 3 days of the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of fluoride toothpaste (1500 ppm F, Crest) twice a day for 3 days of the study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Application of placebo toothpaste (0 ppm F, Ice Fresh) twice a day for 3 days of the study
Study: NCT02750241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active video game-based intervention
Description: * Attend 12 weekly group session at the UTMB Breast Health Clinic to play the active video games using Wii Fit U or Xbox 360.~* Participate in self-paced home sessions~* Monitor daily, weekly, and monthly steps using Wii Fit Meter~* Feedback on physical activity and physical function

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer
Description: * Attend 3 monthly UTMB Breast Cancer Support Group Sessions~* Monitor daily, weekly, and monthly steps using a pedometer (Digi-walker CW-700/701)~* Feedback on physical activity and physical function
Study: NCT00641641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir + emtricitabine + raltegravir.
Description: TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.
Study: NCT03521778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial Distortion Model
Description: Patients will receive manual treatment according to FDM procedures:~1. Triggerbands - therapist put a pressure by the thumb along the presented pathway.~2. Continuum Distortions - therapist put a pressure by the thumb at the exact place of feeling of pain.~3. Folding Distortions - therapist conduct traction or compression of the affected joint.~4. Herniated Triggerpoint - therapist put a pressure by the thumb at the place where HTP occurs.~5. Cylinder Distortions - therapist compress and stretch by the hands affected area.~6. Tectonic Fixation - Therapist compress and stretch affected area by the hands or tools like vacuum bubble.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Concept
Description: Patients will receive manual treatment according to Mulligan Concept procedures:~MWM- Mobilization With Movement- application can be defined as the application of a sustained passive force/glide.~NAG - Natural Apophyseal Glide - application can be defined as the oscillatory mobilization techniques from the middle to the end of the range of motion.~SNAG- Sustained Natural Apophyseal Glide- They are weight bearing techniques: all procedures are done with the patient sitting or in standing. They are mobilisations with active movement followed by passive over pressure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physiotherapy
Description: Patients will receive traditional physiotherapy:~Exercises, laser treatment, magnetic field therapy, ultrasound treatment, light treatment
Study: NCT04894877

Intervention type: PROCEDURE
Intervention: cardiac catheterization
Description: Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.

Intervention type: PROCEDURE
Intervention: coronary artery bypass graft surgery
Description: Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart.

Intervention type: PROCEDURE
Intervention: percutaneous coronary intervention
Description: Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.

Intervention type: BEHAVIORAL
Intervention: Lifestyle
Description: diet, physical activity, smoking cessation

Intervention type: DRUG
Intervention: Medication
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
Study: NCT04468997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug 601
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.